Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>Natera is a leader in the high-growth cell-free DNA (cfDNA) testing market, with a strong portfolio spanning women's health (Panorama), oncology (Signatera), and organ health (Prospera).</li>
  <li>The company is experiencing rapid revenue growth, driven by the strong uptake of its Signatera test for cancer monitoring, and is demonstrating significant operational leverage with improving gross margins and a clear trajectory towards positive free cash flow.</li>
  <li>While the company's proprietary SNP-based technology provides a competitive advantage, Natera faces significant risks related to reimbursement uncertainty, intense competition, and the need to achieve sustained profitability after a history of net losses.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Natera is a leader in the high-growth cell-free DNA (cfDNA) testing market, with a strong portfolio spanning women's health (Panorama), oncology (Signatera), and organ health (Prospera).
  The company is experiencing rapid revenue growth, driven by the strong uptake of its Signatera test for cancer monitoring, and is demonstrating significant operational leverage with improving gross margins and a clear trajectory towards positive free cash flow.
  While the company's proprietary SNP-based technology provides a competitive advantage, Natera faces significant risks related to reimbursement uncertainty, intense competition, and the need to achieve sustained profitability after a history of net losses.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Natera reported a promising financial and operational performance for Q2 2025.</li><li>The company's revenue reached $547 million, representing a 32% year-on-year increase, which, when excluding revenue adjustments, marked an organic growth of 34%.</li><li>This performance was bolstered by substantial demand for its oncology products, particularly Signatera, which saw a record of 189,000 processed tests during the quarter.</li></ul>

Natera reported a promising financial and operational performance for Q2 2025.The company's revenue reached $547 million, representing a 32% year-on-year increase, which, when excluding revenue adjustments, marked an organic growth of 34%.This performance was bolstered by substantial demand for its oncology products, particularly Signatera, which saw a record of 189,000 processed tests during the quarter.

Natera Inc.: An Insight Into Its Strategic Collaborations, AI Initiatives & Other Major Drivers!

<ul><li>Natera, Inc. reported strong financial results for the first quarter of 2025, highlighting significant revenue growth and operational achievements, which present a mixed yet promising outlook for potential investors.</li><li>The company reported a notable increase in revenue to $502 million, up 37% from $368 million in the same period last year.</li><li>This growth was driven by high demand across multiple product lines, particularly within women's health and the oncology segment, where Signatera clinical volumes grew by 52% year-on-year.</li></ul>

Natera, Inc. reported strong financial results for the first quarter of 2025, highlighting significant revenue growth and operational achievements, which present a mixed yet promising outlook for potential investors.The company reported a notable increase in revenue to $502 million, up 37% from $368 million in the same period last year.This growth was driven by high demand across multiple product lines, particularly within women's health and the oncology segment, where Signatera clinical volumes grew by 52% year-on-year.

Natera Inc.: Is The Recent Growth in Signatera Volumes Here To Stay?

<ul><li>Natera Inc. presented its fourth quarter 2024 financial results, signaling a robust period for the company as they continue to expand and enhance their operations.</li><li>The company's revenues for the quarter reached $476 million, marking a substantial 53% increase year-on-year and exceeding their January pre-announcement by $4 million.</li><li>This robust revenue growth is attributed to an increase in test volumes across their product lines, with a particular highlight on the 60% clinical volume growth of Signatera compared to the fourth quarter of 2023.</li></ul>

Natera Inc. presented its fourth quarter 2024 financial results, signaling a robust period for the company as they continue to expand and enhance their operations.The company's revenues for the quarter reached $476 million, marking a substantial 53% increase year-on-year and exceeding their January pre-announcement by $4 million.This robust revenue growth is attributed to an increase in test volumes across their product lines, with a particular highlight on the 60% clinical volume growth of Signatera compared to the fourth quarter of 2023.

Natera Inc.: Strong Execution in Revenue Per Test Powering Our Optimism!

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Single-Molecule precision enables highly accurate, scalable tests across prenatal and oncology diagnostics, setting BillionToOne apart from traditional sequencing-based competitors.</li>
<li>BillionToOne delivers 100%+ revenue growth, 69% gross margins, and positive EBITDA—rare performance metrics in molecular diagnostics ahead of its $2.3B IPO.</li>
<li>IPO is multiple-times oversubscribed with long-only healthcare anchors and top-tier backers, signaling strong institutional confidence ahead of pricing.</li>
</ul>


Single-Molecule precision enables highly accurate, scalable tests across prenatal and oncology diagnostics, setting BillionToOne apart from traditional sequencing-based competitors.
BillionToOne delivers 100%+ revenue growth, 69% gross margins, and positive EBITDA—rare performance metrics in molecular diagnostics ahead of its $2.3B IPO.
IPO is multiple-times oversubscribed with long-only healthcare anchors and top-tier backers, signaling strong institutional confidence ahead of pricing.


BillionToOne (BLLN) IPO: High-Growth Molecular Diagnostics Firm Captures Strong Investor Interest

United States

Natera, Inc. operates as a diagnostics company. The Company provides preconception and prenatal genetic testing services. Natera also offers pre-implantation genetic diagnosis, aneuploidy screening, translocation, and single gene testing services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Natera Inc (NTRA US)

Primer: Natera Inc (NTRA US) - Nov 2025

Natera is a leader in the high-growth cell-free DNA (cfDNA) testing market, with a strong portfolio spanning women's health (Panorama), oncology...

αSK

Natera Inc.: An Insight Into Its Strategic Collaborations, AI Initiatives & Other Major Drivers!

Natera reported a promising financial and operational performance for Q2 2025. The company's revenue reached $547 million, representing a 32%...

Baptista Research

Natera Inc.: Is The Recent Growth in Signatera Volumes Here To Stay?

Natera, Inc. reported strong financial results for the first quarter of 2025, highlighting significant revenue growth and operational...

Baptista Research

Natera Inc.: Strong Execution in Revenue Per Test Powering Our Optimism!

Natera Inc. presented its fourth quarter 2024 financial results, signaling a robust period for the company as they continue to expand and enhance...

Baptista Research

BillionToOne (BLLN) IPO: High-Growth Molecular Diagnostics Firm Captures Strong Investor Interest

BillionToOne's single-molecule precision technology sets them apart in prenatal and oncology diagnostics, leading to impressive revenue growth and...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Natera Inc (NTRA US) - Nov 2025

Natera is a leader in the high-growth cell-free DNA (cfDNA) testing market, with a strong portfolio spanning women's health (Panorama), oncology...

αSK

Natera Inc.: An Insight Into Its Strategic Collaborations, AI Initiatives & Other Major Drivers!

Natera reported a promising financial and operational performance for Q2 2025. The company's revenue reached $547 million, representing a 32%...

Baptista Research

Natera Inc.: Is The Recent Growth in Signatera Volumes Here To Stay?

Natera, Inc. reported strong financial results for the first quarter of 2025, highlighting significant revenue growth and operational...

Baptista Research

Natera Inc.: Strong Execution in Revenue Per Test Powering Our Optimism!

Natera Inc. presented its fourth quarter 2024 financial results, signaling a robust period for the company as they continue to expand and enhance...

Baptista Research

BillionToOne (BLLN) IPO: High-Growth Molecular Diagnostics Firm Captures Strong Investor Interest

​BillionToOne's single-molecule precision technology sets them apart in prenatal and oncology diagnostics, leading to impressive revenue growth and...

IPO Boutique

BillionToOne's single-molecule precision technology sets them apart in prenatal and oncology diagnostics, leading to impressive revenue growth and...